Clinical Trial Update: Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating haploidentical donor natural killer cell infusion with IL-15 in patients with acute myeloid leukemia and myelodysplastic syndrom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Haploidentical donor natural killer cell infusion with IL-15 (haploidentical donor natural killer cells with interleukin-15)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED